298 related articles for article (PubMed ID: 23689510)
1. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor.
Ravn P; Madhurantakam C; Kunze S; Matthews E; Priest C; O'Brien S; Collinson A; Papworth M; Fritsch-Fredin M; Jermutus L; Benthem L; Gruetter M; Jackson RH
J Biol Chem; 2013 Jul; 288(27):19760-72. PubMed ID: 23689510
[TBL] [Abstract][Full Text] [Related]
2. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling.
Malde AK; Srivastava SS; Coutinho EC
J Pept Sci; 2007 May; 13(5):287-300. PubMed ID: 17437246
[TBL] [Abstract][Full Text] [Related]
3. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
4. Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor.
Smit FX; van der Velden WJC; Kizilkaya HS; Nørskov A; Lückmann M; Hansen TN; Sparre-Ulrich AH; Qvotrup K; Frimurer TM; Rosenkilde MM
Structure; 2021 Jul; 29(7):679-693.e6. PubMed ID: 33891864
[TBL] [Abstract][Full Text] [Related]
5. GIP(3-30)NH
Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist.
Lewis JT; Dayanandan B; Habener JF; Kieffer TJ
Endocrinology; 2000 Oct; 141(10):3710-6. PubMed ID: 11014226
[TBL] [Abstract][Full Text] [Related]
7. Human GIP(3-30)NH
Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
[TBL] [Abstract][Full Text] [Related]
8. Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand.
Yaqub T; Tikhonova IG; Lättig J; Magnan R; Laval M; Escrieut C; Boulègue C; Hewage C; Fourmy D
Mol Pharmacol; 2010 Apr; 77(4):547-58. PubMed ID: 20061446
[TBL] [Abstract][Full Text] [Related]
9. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
10. Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations.
Tikhele SH; Pissurlenkar RR; Srivastava S; Saran A; Coutinho EC
J Pept Sci; 2010 Aug; 16(8):383-91. PubMed ID: 20607844
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
12. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
[TBL] [Abstract][Full Text] [Related]
13. Insights into agonist-elicited activation of the human glucose-dependent insulinotropic polypeptide receptor.
Yuliantie E; van der Velden WJC; Labroska V; Dai A; Zhao F; Darbalaei S; Deganutti G; Xu T; Zhou Q; Yang D; Rosenkilde MM; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2021 Oct; 192():114715. PubMed ID: 34339714
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
15. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
16. The role of GIP in α-cells and glucagon secretion.
El K; Campbell JE
Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
[TBL] [Abstract][Full Text] [Related]
17. Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist.
Ismail S; Dubois-Vedrenne I; Laval M; Tikhonova IG; D'Angelo R; Sanchez C; Clerc P; Gherardi MJ; Gigoux V; Magnan R; Fourmy D
Mol Cell Endocrinol; 2015 Oct; 414():202-15. PubMed ID: 26225752
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular biology of the GIP receptor.
Greenwell AA; Chahade JJ; Ussher JR
Peptides; 2020 Mar; 125():170228. PubMed ID: 31812593
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor.
Zhao F; Zhang C; Zhou Q; Hang K; Zou X; Chen Y; Wu F; Rao Q; Dai A; Yin W; Shen DD; Zhang Y; Xia T; Stevens RC; Xu HE; Yang D; Zhao L; Wang MW
Elife; 2021 Jul; 10():. PubMed ID: 34254582
[TBL] [Abstract][Full Text] [Related]
20. Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.
Venneti KC; Malthouse JP; O'Harte FP; Hewage CM
Biochim Biophys Acta; 2011 Jul; 1814(7):882-8. PubMed ID: 21539943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
